Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2006

View Archived Issues

GYKI-16084 improves symptoms in benign prostatic hyperplasia

Phase I study data support fixed dosing of ABT-751 in cancer patients

Effect of sildenafil on peak systolic velocity a mechanism of erection improvement

Advanced Cell Technology announces timetables for IND filings in key therapeutic programs

Advaxis reports update of Listeria-based vaccines

Hemispherx Biopharma to conduct influenza vaccine/immunopotentiation phase II clinical trial

PhytoMedical Technologies' BDC-O3 holds potential for atherosclerosis

Patient enrollment complete for X-Cell Medical's ETHOS II estradiol-eluting stent trial

Marshall Edwards achieves SPA for pivotal trial of phenoxodiol

Patient enrollment complete in phase III trial of telavancin for cSSSI

More positive data reported for Nymox's BPH drug candidate

BioMS Medical receives approval to begin phase II RRMS trial

Phase II trial of Manhattan Pharmaceutical's obesity drug candidate cleared in Switzerland

Shire provides update on Elaprase's registration process

Migenix receives approval in Canada to begin phase II trial for HCV

Intercept Pharmaceuticals' INT-747 well tolerated in phase Ia study

Lexiva has comparable activity to the preferred HIV protease inhibitor Kaletra

TC-1734 reaches endpoints in age-associated memory impairment phase II trials

Novel antiinfective agents disclosed in recent patent literature

Novel treatment options for metabolic disorders described in recent patents

FDA approves Azilect for Parkinson's disease

Promising camptothecin derivatives developed at Bristol-Meyers Squibb

Actilon granted fast track designation in U.S. as HCV therapy

FDA committee unanimously supports efficacy of Gardasil clinical data

Antisense oligomers effective against different strains of the influenza A virus in vitro

Novel triple reuptake inhibitor shows antidepressant activity in animal models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...